Catalent, Inc. (NYSE: CTLT) has been notified of an unsolicited “mini-tender offer” by TRC Capital Investment Corporation (“TRC”) to purchase up to 2,000,000 shares of Catalent’s common stock at a price of $42.95 per share in cash. This offer price is an astounding 4.43% lower than the closing price of Catalent’s stock on April 24, 2023, just the day before the mini-tender offer was issued. This unexpected offer is one that investors should take seriously, as it stands to potentially offer a substantial discount on this highly sought after stock.
Catalent strongly discourages stockholders from tendering their shares in response to TRC’s unsolicited mini-tender offer, as it is priced below the current market price of Catalent’s common stock and carries various other conditions. Don’t miss out on the opportunity to get the best value for your shares!
TRC has launched a mini-tender offer for shares of Catent, but it is not affiliated or associated in any way with the company. Mini-tender offers are designed to acquire not more than 5 percent of a company’s shares outstanding, avoiding many of the SEC’s investor protections. This means investors may not receive the same level of protection as they would with larger tender offers.
The SEC is warning investors to be aware of mini-tender offers made at below-market prices, as these offers could be an attempt to take advantage of investors who don’t compare the offer price to the current market price. With their “Tips for Investors”, the SEC is helping investors to protect themselves from these unscrupulous bidders.
Stockholders should take note of the current market value of their shares of common stock and consult their broker or financial advisor before making any decisions regarding TRC’s mini-tender offer. Exercise caution and be mindful of the risks that may be involved.
Catalent advises stockholders who have not yet responded to TRC’s mini-tender offer to take no action. For those who have already submitted their shares, they are eligible to withdraw them by providing a written notice as specified in TRC’s offering documents before the mini-tender offer closes on May 24, 2023 at 12:01 a.m. New York City time, unless it is extended or terminated earlier.
Catalent urges all distributors of materials regarding TRC’s mini-tender offer to include a copy of this news release in their distributions.
Catalent, Inc., an S&P 500® company and global leader in the healthcare industry, is dedicated to helping pharma, biotech, and consumer health partners launch and supply products to support the well-being of patients worldwide. With top-notch expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent partners with over 1,000 programs and launches over 150 new products annually.
Operating from over 50 global sites and with an expert workforce of 18,000, Catalent is capable of supplying 80 billion doses of 8,000 products each year, generating $5 billion in revenue annually. Headquartered in Somerset, New Jersey, Catalent is committed to revolutionizing healthcare and making a real impact in the lives of patients.